In summary, as second-line therapy for postmenopausal women with ER-positive and/or PgR-positive advanced breast cancer who have progressed on prior endocrine treatment, fulvestrant is clearly an effective therapy that offers equal efficacy to anastrozole. The gene discussed is PGR; the disease is breast carcinoma.